# Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

> **NCT00368251** · PHASE3 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 56 (actual)

## Conditions studied

- Unverricht-Lundborg Disease

## Interventions

- **OTHER:** Placebo
- **DRUG:** BRV 2.5 mg
- **DRUG:** BRV 25 mg
- **DRUG:** BRV 50 mg

## Key facts

- **NCT ID:** NCT00368251
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00368251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00368251, "Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00368251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*